Destiny Pharma plc
DEST.L · LSE
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | £832 | £154 | £135 | £12 |
| % Growth | 438.2% | 14.4% | 984.6% | – |
| Cost of Goods Sold | £6 | £12 | £13 | £17 |
| Gross Profit | £825 | £142 | £123 | -£4 |
| % Margin | 99.3% | 92% | 90.7% | -35.6% |
| R&D Expenses | £1,767 | £3,272 | £2,383 | £3,222 |
| G&A Expenses | £7,568 | £7,931 | £6,422 | £6,565 |
| SG&A Expenses | £5,629 | £4,602 | £4,038 | £3,315 |
| Sales & Mktg Exp. | -£6 | -£3,329 | -£2,384 | -£3,250 |
| Other Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Expenses | £7,395 | £7,874 | £6,421 | £6,537 |
| Operating Income | -£6,570 | -£7,886 | -£6,434 | -£6,553 |
| % Margin | -790.1% | -5,104.4% | -4,764.7% | -52,638.3% |
| Other Income/Exp. Net | £124 | £65 | £16 | £72 |
| Pre-Tax Income | -£6,446 | -£7,712 | -£6,271 | -£6,481 |
| Tax Expense | -£789 | -£1,208 | -£932 | -£1,070 |
| Net Income | -£5,657 | -£6,504 | -£5,339 | -£5,411 |
| % Margin | -680.3% | -4,209.5% | -3,954.4% | -43,462.5% |
| EPS | -0.062 | -0.093 | -0.089 | -0.12 |
| % Growth | 32.6% | -3.8% | 25.7% | – |
| EPS Diluted | -0.062 | -0.093 | -0.089 | -0.12 |
| Weighted Avg Shares Out | 90,671 | 70,201 | 59,868 | 45,232 |
| Weighted Avg Shares Out Dil | 90,671 | 70,201 | 59,868 | 45,232 |
| Supplemental Information | – | – | – | – |
| Interest Income | £290 | £65 | £16 | £72 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £6 | £12 | £13 | £17 |
| EBITDA | -£6,564 | -£7,764 | -£6,274 | -£6,536 |
| % Margin | -789.3% | -5,025.3% | -4,646.8% | -52,495% |